Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L D Lewis

Showing results (91-100 of 105) with videos related to

Pageof 11
Sort By:
Clinical Pharmacology and Therapeutics|November 14, 1997
Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interactionL D Lewis, A Benin, C L Szumlanski, et al.
American Journal of Veterinary Research|December 1, 1991
Effects of dietary fiber supplementation on glycemic control in dogs with alloxan-induced diabetes mellitusR W Nelson, S L Ihle, L D Lewis, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 11, 1999
Escalating multiple-dose safety and tolerance study of oral WR 6026 in HIV-infected subjects: AIDS clinical trials group 173B G Petty, J R Black, C W Hendrix, et al.
Journal of Hematotherapy|October 1, 1995
Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neuF H Valone, P A Kaufman, P M Guyre, et al.
Clinical Pharmacology and Therapeutics|January 12, 2017
A Pharmacokinetic and Safety Study of Trebananib, an Fc-Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal DysfunctionB Wu, L D Lewis, R D Harvey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1995
Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neuF H Valone, P A Kaufman, P M Guyre, et al.
Journal of Veterinary Internal Medicine|December 26, 2006
Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing catsM C McEntee, K M Rassnick, D B Bailey, et al.
Archives of Biochemistry and Biophysics|July 24, 1998
Induction of cytochrome P4503A by taxol in primary cultures of human hepatocytesV E Kostrubsky, L D Lewis, S C Strom, et al.
Journal of Immunological Methods|February 27, 2001
Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neuL D Lewis, B F Cole, P K Wallace, et al.
Leukemia|August 24, 2007
Aplidin synergizes with cytosine arabinoside: functional relevance of mitochondria in Aplidin-induced cytotoxicityR Humeniuk, L G Menon, P J Mishra, et al.
Pageof 11

Showing results (91-100 of 105) with videos related to

Sort By:
Pageof 11
Clinical Pharmacology and Therapeutics|November 14, 1997
Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interactionL D Lewis, A Benin, C L Szumlanski, et al.
American Journal of Veterinary Research|December 1, 1991
Effects of dietary fiber supplementation on glycemic control in dogs with alloxan-induced diabetes mellitusR W Nelson, S L Ihle, L D Lewis, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 11, 1999
Escalating multiple-dose safety and tolerance study of oral WR 6026 in HIV-infected subjects: AIDS clinical trials group 173B G Petty, J R Black, C W Hendrix, et al.
Journal of Hematotherapy|October 1, 1995
Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neuF H Valone, P A Kaufman, P M Guyre, et al.
Clinical Pharmacology and Therapeutics|January 12, 2017
A Pharmacokinetic and Safety Study of Trebananib, an Fc-Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal DysfunctionB Wu, L D Lewis, R D Harvey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1995
Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neuF H Valone, P A Kaufman, P M Guyre, et al.
Journal of Veterinary Internal Medicine|December 26, 2006
Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing catsM C McEntee, K M Rassnick, D B Bailey, et al.
Archives of Biochemistry and Biophysics|July 24, 1998
Induction of cytochrome P4503A by taxol in primary cultures of human hepatocytesV E Kostrubsky, L D Lewis, S C Strom, et al.
Journal of Immunological Methods|February 27, 2001
Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neuL D Lewis, B F Cole, P K Wallace, et al.
Leukemia|August 24, 2007
Aplidin synergizes with cytosine arabinoside: functional relevance of mitochondria in Aplidin-induced cytotoxicityR Humeniuk, L G Menon, P J Mishra, et al.
Pageof 11